Edition:
United Kingdom

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
15 Dec 2017
Change (% chg)

$-0.02 (-1.16%)
Prev Close
$1.73
Open
$1.73
Day's High
$1.74
Day's Low
$1.70
Volume
30,334
Avg. Vol
88,458
52-wk High
$10.90
52-wk Low
$1.53

Chart for

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)
No analyst recommendations are available for .

Overall

Beta: 3.74
Market Cap(Mil.): $22.80
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia​

07 Sep 2017

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

23 Aug 2017

BRIEF-Cyclacel Pharmaceuticals Q2 loss per share $0.50

* Cyclacel Pharmaceuticals reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Intra-Cellular Therapies reports Q2 loss per share $0.41

* Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update

09 Aug 2017

BRIEF-Cyclacel announces selection of recommended phase 2 dose for CYC065

* Cyclacel announces selection of recommended phase 2 dose for CYC065 and evidence of durable target engagement and MCL-1 biomarker suppression Source text for Eikon: Further company coverage:

07 Aug 2017

BRIEF-Cyclacel announces pricing of $13.2 mln underwritten public offering

* Cyclacel announces pricing of $13.2 million underwritten public offering

19 Jul 2017

BRIEF-Cyclacel Pharmaceuticals says approved extension of employment agreements with CEO and CFO

* Cyclacel pharmaceuticals - compensation and organization development committee approved extension of employment agreements with ceo spiro rombotis, cfo paul mcbarron

27 Jun 2017

Competitors

Earnings vs. Estimates